13F HOLDINGS REPORT
Wildcat Capital Management, LLC
Quarter ended Q1 2025 · Filed May 2, 2025 · Accession 0001999371-25-005352
Total Value
$187.4M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | FRONTIER GROUP HLDGS INC | ULCC | 28,061,351 | $121.8M | 64.99% |
| 2 | RLX TECHNOLOGY INC | RLX | 18,046,195 | $33.9M | 18.11% |
| 3 | ACUREN CORP | TICAW | 1,500,000 | $16.7M | 8.90% |
| 4 | UROGEN PHARMA LTD | URGN | 495,606 | $5.5M | 2.93% |
| 5 | ALLOGENE THERAPEUTICS INC | ALLO | 2,920,787 | $4.3M | 2.28% |
| 6 | CENTESSA PHARMACEUTICALS PLC | CNTA | 281,859 | $4.1M | 2.16% |
| 7 | KRONOS BIO INC | 50107A104 | 1,297,959 | $1.1M | 0.57% |
| 8 | SILEXION THERAPEUTICS CORP | SLXNW | 113,428 | $124,771 | 0.07% |